

Latest Adacel shortage update for 2026. Get the facts on Tdap vaccine supply, what's causing availability issues, and what patients should do right now.
If you've been following the Adacel availability situation, here's the latest: while Adacel is not in an official FDA-listed drug shortage, patients across the United States continue to face difficulty finding this Tdap vaccine at their local pharmacies. The availability issues that began in late 2024 persist into 2026, driven by a complex chain of events in the vaccine supply landscape.
This article provides an up-to-date overview of the Adacel shortage situation, what's causing it, and practical advice for patients who need this vaccine.
Here's the situation as of early 2026:
Understanding the timeline helps explain why Adacel is hard to find:
MassBiologics, a nonprofit vaccine manufacturer, permanently stopped producing TdVax — one of only a few Td (tetanus-diphtheria) vaccines available in the U.S. This left Tenivac (Sanofi Pasteur) as essentially the sole Td vaccine on the market.
As Td supplies tightened, the CDC issued guidance recommending healthcare providers use Tdap vaccines (Adacel and Boostrix) as substitutes for Td "whenever possible." This was a practical solution, but it shifted enormous demand onto the Tdap supply chain.
Pharmacies, hospitals, and clinics began using Adacel in situations previously handled by Td — routine adult boosters, wound care tetanus prophylaxis, and more. This increased demand outpaced existing production capacity and distribution planning.
The FDA approved updated labeling for Adacel allowing repeat vaccination after 8 years, further expanding the eligible patient population and contributing to sustained demand.
Sanofi Pasteur has been working to increase production, but vaccine manufacturing takes months per batch. The situation is improving but hasn't fully normalized. For a deeper dive, read our article on why Adacel is so hard to find.
Routine Tdap boosters are important but not typically urgent. If your pharmacy doesn't have Adacel:
The CDC recommends a Tdap booster during weeks 27-36 of every pregnancy to pass protective antibodies to your baby. This is especially important for protecting newborns from pertussis, which can be life-threatening in young infants.
Don't delay this vaccination. If Adacel isn't available:
Emergency departments and urgent care clinics typically stock Tdap for wound care. If you sustain a wound and need tetanus protection:
Many healthcare employers require current Tdap vaccination. If you're having trouble finding Adacel for an employer requirement:
Here's a quick reference for where to check:
For a complete walkthrough, see our guide: How to find Adacel in stock near you.
The shortage doesn't change your insurance coverage. Under the ACA, Tdap vaccines remain a covered preventive service at no cost when administered by an in-network provider. This applies whether you receive Adacel or Boostrix.
If you're paying out of pocket, cash prices for Adacel typically range from $49 to $95. Discount cards from GoodRx or SingleCare may help reduce costs. For more savings strategies, check out our article on how to save money on Adacel.
There's no firm end date, but several factors point toward gradual improvement:
Realistically, intermittent spot shortages may continue through 2026. The best strategy is to be proactive — search multiple sources, be flexible about which Tdap product you receive, and don't wait until the last minute.
To keep track of the Adacel availability situation:
The Adacel availability challenges of 2026 are real but manageable. The vaccine is still being made, alternatives like Boostrix exist, and multiple avenues are available to help you get vaccinated. Stay proactive, be flexible, and use tools like MedFinder to find what you need.
Your protection against tetanus, diphtheria, and pertussis is worth the extra effort. Don't let a temporary supply crunch leave you unvaccinated.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.